A company headquartered in Chicago has put a new digital instrument in front of cardiologists, built on a quiet but persistent problem: a patient's heart history lives scattered across many records, and atrial fibrillation, the most common rhythm disturbance seen in clinics, slips through those gaps. The tool, CardioVisio for AFib, gathers that fragmented past into a single visual account and proposes treatments aligned with current guidelines, offered for now in the United States. Whether it will truly alter how often this condition is caught and treated is a question the announcement leaves
GE HealthCare Launches CardioVisio for AFib, a Digital Tool for Longitudinal Atrial Fibrillation Decision Support
A tool to tell the story of the heart
A company headquartered in Chicago has put a new digital instrument in front of cardiologists, built on a quiet but persistent problem: a patient's heart history lives scattered across many records, and atrial fibrillation, the most common rhythm disturbance seen in clinics, slips through those gaps. The tool, CardioVisio for AFib, gathers that fragmented past into a single visual account and proposes treatments aligned with current guidelines, offered for now in the United States. Whether it will truly alter how often this condition is caught and treated is a question the announcement leaves open, to be answered by time and by those who test it.
GE HealthCare, based in Chicago, has launched CardioVisio for AFib, a digital tool built around a familiar frustration in cardiology: the story of a patient's heart is spread across many records, and atrial fibrillation is easy to overlook or undertreat.
The company points to sobering figures. Cardiovascular disease leads the world in deaths, and atrial fibrillation is the most common arrhythmia found in clinical settings. Yet it is often misdiagnosed, with routine practice reportedly missing up to 30 percent of cases. People with the condition face a fivefold higher stroke risk, and it frequently leads to hospital admission.
CardioVisio pulls data from several sources, analyzes it over time, and presents a patient's cardiac history visually, so clinicians can see how the disease has moved. It then offers therapy suggestions that follow updated AFib guidelines. The company stresses that each automated step is transparent and traceable, so providers can review and revise the results, tailoring care rather than issuing a fixed answer.
Eigil Samset, general manager of Cardiology Solutions, described existing care models as complex, time-consuming and disconnected, with guidelines that diverge and uneven adherence. The tool, he said, gives cardiologists a way to tell the heart's story in full, from past diagnoses and medications to interventions and comorbidities.
The tool is available now in the United States, with more regional guidelines planned. The announcement offers no clinical outcome data, so whether it truly improves detection or patient results is yet to be shown. Expansion and independent evaluation are what to watch next.
GE HealthCare, based in Chicago, has launched a digital tool called CardioVisio for AFib, aimed at a problem cardiologists know well: the full story of a patient's heart is scattered across records, and atrial fibrillation is easy to miss or undertreat when it is.
The case for the tool starts with the numbers the company and the report cite. Cardiovascular diseases are the world's leading cause of death, and more than 60 percent of those deaths are described as both preventable and untimely. Within that group, atrial fibrillation is the most common arrhythmia identified in clinical settings, affecting people worldwide.
Despite how common it is, AFib is often misdiagnosed or inadequately treated. The source says routine clinical practice overlooks up to 30 percent of cases. The stakes are concrete: people with the condition face a fivefold higher risk of stroke, and AFib is a frequent cause of hospitalization.
CardioVisio for AFib is built as a patient-centric clinical decision support tool. It pulls in data from several sources, analyzes it over time, and lays out the patient's cardiac history visually so a clinician can follow how the disease has progressed. On top of that, it offers therapy recommendations that conform to updated AFib guidelines. GE HealthCare says this saves clinicians time as well as supporting their decisions.
The company also stresses oversight. Every automated step is meant to be transparent and traceable, so healthcare providers can review the process and the results and revise them. The stated aim is to tailor care to the particular needs of each AFib patient rather than hand down a fixed answer.
Eigil Samset, PhD, general manager of Cardiology Solutions at GE HealthCare, described the gap the product is meant to fill. Existing diagnosis and treatment models for AFib, he said, have been shown to be complex, time consuming and disconnected, with disparate guidelines and poor adherence to them. With CardioVisio, he said, cardiologists get a tool to tell the story of the heart, including previous diagnoses, prescribed medications, interventions and comorbidities.
The tool is available now in the United States. GE HealthCare plans to widen its reach over the following months, adding other regional guidelines. The announcement does not report clinical outcome data, so whether the tool changes detection rates or patient results remains to be shown. Expansion and any independent evaluation are the things to watch.
Citações Notáveis
Existing AFib diagnosis and treatment models are complex, time consuming and disconnected, with disparate guidelines and poor adherence; CardioVisio gives cardiologists a tool to tell the story of the heart.— Eigil Samset, PhD, general manager, Cardiology Solutions, GE HealthCare
Quer a matéria completa?
Leia o original em HospiMedica ↗
Health & Medicine